

Leading Factor Driving The Rekovelle Market In 2025: Rising Infertility Rates Drive Market Growth In IVF Treatments

The Business Research Company's Leading Factor Driving The Rekovelle Market In 2025: Rising Infertility Rates Drive Market Growth In IVF Treatments

LONDON, GREATER LONDON, UNITED KINGDOM, March 12, 2025

[/EINPresswire.com/](https://www.einpresswire.com/) -- Updated 2025

Market Reports Released: Trends,

Forecasts to 2034 – Early Purchase Your Competitive Edge Today!



The Business
Research Company

Rekovelle Market Report 2025

Are you aware that the Rekovelle market has experienced notable growth in recent years, with a substantial Compound Annual Growth Rate (CAGR)?



It will grow to \$XX million in 2029 at a compound annual growth rate (CAGR) of XX%."

The Business Research Company

- What is the expected market growth?
 - o The market is projected to expand from \$XX million in 2024 to \$XX million in 2025.
 - o This reflects a CAGR of XX%.
- What factors are driving this growth?
 - o Increasing demand for non-invasive testing methods.
 - o A growing preference for non-invasive and convenient delivery methods.

- o Expanding use of IVF procedures.
- o Rising interest in female fertility preservation.
- o Greater awareness of post-menopausal health concerns.

Get Your Free Sample Market Report:

<https://www.thebusinessresearchcompany.com/sample.aspx?id=20275&type=smp>

How will the Rekovelle market grow in the coming years?

- o The market size is forecasted to reach \$XX million by 2029.
- o It is expected to grow at a CAGR of XX% during the forecast period.
- What are the key drivers of future growth?

- o Increasing incidence of genetic disorders.
- o A rise in hormonal disorder prevalence.
- o Higher global adoption of IVF treatments.
- o Expansion of IVF centers and fertility clinics.
- o High prevalence of hypogonadism.
- What trends will shape the market?
- o Integration with fertility preservation methods.
- o Innovations in hormone replacement therapy (HRT) products.
- o Advancements in IVF technology and equipment.
- o Improved fertility treatment technologies.
- o Combination of testosterone replacement therapy (TRT) with wellness and anti-aging treatments.

Order Your Report Now For A Swift Delivery:

<https://www.thebusinessresearchcompany.com/report/rekovellev-global-market-report>

What is driving the growth in the Rekovelle market?

One of the primary growth factors is the increasing infertility rate. Infertility rates represent the proportion of individuals or couples within a population unable to conceive after a specified period—typically one year—despite engaging in regular, unprotected sexual intercourse. Multiple factors contribute to rising infertility rates, including delayed childbearing, lifestyle modifications, exposure to environmental toxins, and underlying medical conditions. These factors have significantly increased the demand for fertility treatments. Rekovelle plays a crucial role by enhancing ovarian responsiveness, thereby improving the effectiveness of assisted reproductive technologies like IVF. As a result, the likelihood of successful fertilization and pregnancy increases. According to the World Health Organization (WHO), as of April 2023, approximately 17.5% of the global adult population—or one in six individuals—experience infertility. This rising prevalence is fueling the demand for Rekovelle treatments.

Which companies are leading in the Rekovelle market?

A key player in the industry is Ferring Pharmaceuticals A/S, recognized for its commitment to quality, innovation, and integrity.

What is the latest emergent trend in the Rekovelle market?

One significant trend involves ongoing research aimed at optimizing Rekovelle as a personalized ovarian stimulation treatment. Studies are being conducted to assess its safety, efficacy, and optimal clinical applications. Notably, in March 2023, Ferring Pharmaceuticals A/S presented results from the PROFILE study—the first real-world, prospective study on Rekovelle (follitropin delta). Key findings include:

- Approximately 74% of participants retrieved between 4 and 19 oocytes.
- Ongoing pregnancy rates aligned with previous Phase 3 trials.
- An individualized dosing algorithm, based on body weight and anti-Müllerian hormone levels, was used in 95% of cases.

How is the global Rekovelle market segmented?

1. By Indication:

- o Controlled Ovarian Stimulation
- o Polycystic Ovary Syndrome

2. By Distribution Channel:

- o Hospitals
- o Clinics
- o Pharmacies

3. By End User:

- o Pediatric
- o Adult
- o Geriatric

Which regions are leading in the Rekovelle market?

Europe was the largest market for Rekovelle in 2024, while the Asia-Pacific region is expected to exhibit the highest growth rate during the forecast period. The market report covers regions including Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

Browse For More Similar Reports-

Infertility Treatment Global Market Report 2025

<https://www.thebusinessresearchcompany.com/report/infertility-treatment-global-market-report>

Hormone Therapy Global Market Report 2025 –

<https://www.thebusinessresearchcompany.com/report/hormone-therapy-global-market-report>

Parathyroid Hormone Global Market Report 2025

<https://www.thebusinessresearchcompany.com/report/parathyroid-hormones-global-market-report>

Learn More About [The Business Research Company](#)

The Business Research Company provides in-depth research and insights through a vast collection of 15,000+ reports spanning 27 industries and over 60 geographies. Backed by 1,500,000 datasets, extensive secondary research, and expert insights from industry leaders, we equip you with the knowledge needed to stay ahead in the market.

Our flagship offering, the Global Market Model, is a leading market intelligence platform that delivers comprehensive and up-to-date forecasts to support strategic decision-making.

Contact Us:

The Business Research Company

Europe: +44 207 1930 708

Asia: +91 88972 63534

Americas: +1 315 623 0293

Email: info@tbrc.info

Follow Us On:

LinkedIn: <https://in.linkedin.com/company/the-business-research-company>

Twitter: https://twitter.com/tbrc_info

YouTube: https://www.youtube.com/channel/UC24_f10rV8cR5DxICpgmyFQ

Oliver Guirdham

The Business Research Company

+44 20 7193 0708

info@tbrc.info

Visit us on social media:

[Facebook](#)

[X](#)

[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/792766900>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.